The biotech stocks billionaires are buying and selling right now

By maria collazo
Share

The wave of consolidations in the health space is attracting top hedge fund billionaires, with biotech stocks being some of the most popular.

As recently reported by our sister publication Healthcare Global, Forbes recently compiled a list of the stocks the richest hedge fund billionaires are looking at, based on those either bought or sold in at least 10,000 shares.

RELATED TOPIC: Investing: 3 silver stocks to watch for

With M&A deals seeing a spike in 2015, the interest in certain stocks shifted. Teva Pharmaceutical, for instance, was one stock that drew “votes of confidence” from investors. Actavis, however, was on both the buying and selling list as hedge fund billionaires can’t seem to agree on whether the latest merger is good or bad news for the company.

Top stocks being bought

1. Actavis

2. Curis  

3. Endo International

4. Teva Pharmaceutical

5. Boston Scientific

Actavis is 24 percent owned by hedge funds. The debate on whether to buy or sell this stock stems from the merger between the Dublin-based drug giant and Botox maker Allergan.

RELATED TOPIC: Is your venture capital on the digital health bandwagon?

Top stocks being sold

1. HCA Holdings

2. Abbvie

3. Actavis

4. Medtronic

5. Shire

HCA Holdings comes at No. 1 on Forbes’ list, as nine hedge fund billionaires cut back their positions at the end of Q1 after the hospital operator’s positive stock return over the past year. The stock, however, jumped 9 percent in June as the Supreme Court ruled to uphold an important part of the Affordable Care Act, benefitting hospital operations.  

RELATED TOPIC: How to spot a dubious investment when stocks are over-performing

To see the complete list, visit Forbes

Let's connect! Like us on Facebook and follow us on Twitter!

Click here to read the latest edition of Business Review USA!

Share

Featured Articles

What is Nestlé CEO Laurent Freixe’s Action Plan?

Newly appointed CEO sets out action plan involving separating water brands into standalone business and boosting advertising and marketing spend

Will Mulberry Turn a New Leaf Under CEO Andrea Baldo?

International British luxury brand cuts quarter of head office staff as newly appointed CEO conducts strategic review

Female Board Members of Biggest UK Companies Paid 69% Less

Female board members of FTSE 100 companies are paid 69% less than male counterparts, as they find themselves frozen out of the biggest roles

Is This the Next CEO of LVMH?

Leadership & Strategy

How Burberry’s New CEO Is Going Back to Basics

Leadership & Strategy

Is Bayer CEO Bill Anderson Running Out of Time?

Leadership & Strategy